HGF and myeloid sarcoma: Therefore, at the RR-MS stage of the disease, circulating levels of the β-chemokines MCP-1/CCL2, Eotaxin/CCL11 and of the growth factor HGF, were diminished with respect to other MS clinical forms and to healthy controls, suggesting a potential role for these diminished molecules in the initial stages of MS pathogenesis.